B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart to $1.50 from $6 and keeps a Neutral rating on the shares. The target drop reflects a more conservative estimate of ramp-up of Norovirus and peak market penetration from 35% to 24%, Mamtani tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VXRT: